BeiGene Stock Rises on FDA Approval for Cancer Treatment
| BGNEDelisted Stock | USD 184.71 0.71 0.39% |
About 56% of BeiGene's investor base is looking to short. The analysis of current outlook of investing in BeiGene suggests that many traders are alarmed regarding BeiGene's prospects. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
BeiGene saw a pre-market increase of 1.16, reaching 184. The rise follows the announcement that the U.S. Food and Drug Administration has approve
Read at gurufocus.com
 |
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
BeiGene is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
| IMAB | I Mab | 3.30 | ||||
| LEGN | Legend Biotech | 3.02 | ||||
| PCVX | Vaxcyte | 1.87 | ||||
| ASND | Ascendis Pharma | 1.74 | ||||
| BPMC | Blueprint Medicines | 1.32 | ||||
| KRYS | Krystal Biotech | 1.17 | ||||
| APLS | Apellis Pharmaceuticals | 0.90 | ||||
| ARWR | Arrowhead Pharmaceuticals | 0.71 | ||||
| AKRO | Akero Therapeutics | 0.57 | ||||
| BMRN | Biomarin Pharmaceutical | 0.51 | ||||
| IONS | Ionis Pharmaceuticals | 0.35 | ||||
| INCY | Incyte | 0.14 | ||||
| TVTX | Travere Therapeutics | 0.58 | ||||
| IMVT | Immunovant | 1.51 |
Check out BeiGene Hype Analysis, BeiGene Correlation and BeiGene Performance. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in BeiGene Stock
If you are still planning to invest in BeiGene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BeiGene's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |